



Suggested Formula	Fluticasone Propionate 1%, Pentoxifylline 5%, Tranilast 1% Topical Gel (Suspension, 15 g)	FIN	F 006 470
-------------------	---	-----	-----------

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Fluticasone Propionate, USP	0.150	g				
Pentoxifylline, USP	0.750	g				
Tranilast	0.150	g				
Ethoxy Diglycol	0.7	mL				
Medisca CopaSil™	13.23	g				

SPECIAL PREPARATORY CONSIDERATIONS

Ingredient-Specific Information

Light Sensitive (protect from light whenever possible):

Fluticasone Propionate, Pentoxifylline, Tranilast, CopaSil™

Hygroscopic (protect from moisture whenever possible):

Ethoxy Diglycol

Heat Suggested Preparatory Guidelines

Non-Sterile Preparation Sterile Preparation

Processing Error /

Testing Considerations:

To account for processing error considerations during preparation, it is suggested to measure an additional **15 to 20%** of the required quantities of ingredients.

Special Instruction:

Protective apparel, such as a lab coat, disposable gloves, eyewear and face-masks should always be worn.

This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.



Suggested Formula	Fluticasone Propionate 1%, Pentoxifylline 5%, Tranilast 1% Topical Gel (Suspension, 15 g)	FIN	F 006 470
-------------------	---	-----	-----------

SUGGESTED PREPARATION (for 15 g)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor (*): _____	Processing Error	Qty. to measure
Fluticasone Propionate, USP §	0.150	g			
Pentoxifylline, USP §	0.750	g			
Tranilast §	0.150	g			
Ethoxy Diglycol §	0.7	mL			
Medisca CopaSil™	13.23	g			

§ Weigh / measure just prior to use.

* Takes into account increased batch size conversions and density conversions, if required.

Preparatory Instruction

1.	<p><u>Powder-liquid preparation:</u></p> <p>A. Combine and triturate the following ingredients together to form a fine, homogeneous powder blend:</p> <ul style="list-style-type: none">-Fluticasone Propionate-Pentoxifylline-Tranilast <p>B. Levigate the fine homogeneous powder blend (Step 1A) with the Ethoxy Diglycol.</p> <p><u>End result:</u> Homogeneous paste-like dispersion.</p>
2.	<p><u>Powder-liquid to medium integration:</u></p> <p>A. Incrementally add the homogeneous paste-like dispersion (Step 1B) to the CopaSil™.</p> <p><u>Specifications:</u> Continuously mix, using high-shear mixing techniques.</p> <p><u>End result:</u> Homogeneous gel-like dispersion.</p> <p>B. If the final result is gritty, pass it through the ointment mill until it becomes smooth and uniform.</p>
3.	<p><u>Product transfer:</u></p> <p>Transfer the final product into the specified dispensing container (see “Packaging Requirements”).</p>



Suggested Formula	Fluticasone Propionate 1%, Pentoxifylline 5%, Tranilast 1% Topical Gel (Suspension, 15 g)	FIN	F 006 470
-------------------	---	-----	-----------

SUGGESTED PRESENTATION

Estimated Beyond-Use Date	6 months, as per USP*.	Packaging Requirements	- Tightly closed, light-resistant container. - To be administered with a metered-dose measuring device.	
Auxiliary Labels	1	Use as directed. Do not exceed prescribed dose.	6	Do not take with alcohol, sleep aids, tranquilizers or other CNS depressants.
	2	Keep out of reach of children.	7	Cap tightly after use.
	3	Consult your health care practitioner if any other prescription or over-the-counter medications are currently being used or are prescribed for future use.	8	May impair mental and/or physical ability. Use care when operating a car or machinery.
	4	Keep at room temperature (20°C – 23°C).	9	Keep in a dry place.
	5	For external use only.	10	Protect from light.
Pharmacist Instructions	Add any auxiliary labels specific to the API to the dispensing container as deemed necessary.			
Patient Instructions	Contact your pharmacist in the event of adverse reactions. IMPORTANT: The quantity of API administered is directly dependent on the quantity of product applied.			

* The BUD is not later than the time remaining until the earliest expiration date of any API or 6 months, whichever is earlier.

REFERENCES

1.	Gels. In: Allen, LV, Jr. <i>The Art, Science and Technology of Pharmaceutical Compounding Fourth Edition</i> . American Pharmaceutical Association; 2012: 285.
2.	Flovent HFA. In: Canadian Pharmacists Association. <i>Compendium of Pharmacists and Specialties, 2015</i> : 1239.
3.	Pentoxifylline. In: Canadian Pharmacists Association. <i>Compendium of Pharmacists and Specialties, 2015</i> : 2251.
4.	Diethylene Glycol Monoethyl Ether. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients, 7th Edition</i> . American Pharmaceutical Association; 2012: 256.
5.	Fluticasone Propionate. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference, 36th Edition</i> . London, England: The Pharmaceutical Press; 2009: 1533.
6.	Pentoxifylline. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference, 36th Edition</i> . London, England: The Pharmaceutical Press; 2009: 1367.
7.	Tranilast. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference, 36th Edition</i> . London, England: The Pharmaceutical Press; 2009: 1149.



Suggested Formula	Fluticasone Propionate 1%, Pentoxifylline 5%, Tranilast 1% Topical Gel (Suspension, 15 g)	FIN	F 006 470
-------------------	---	-----	-----------

8.	Fluticasone Propionate (Monograph). In: O'Neil MJ. <i>The Merck Index 15th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2013: Monograph #4240.
9.	Pentoxifylline (Monograph). In: O'Neil MJ. <i>The Merck Index 15th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2013: Monograph #7249.
10.	Tranilast (Monograph). In: O'Neil MJ. <i>The Merck Index 15th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2013: Monograph #9731.
11.	Fluticasone Propionate. In: Trissel LA. <i>Trissel's Stability of Compounded Formulations, 5th Edition</i> . American Pharmaceutical Association; 2012: 215.
12.	Pentoxifylline. In: Trissel LA. <i>Trissel's Stability of Compounded Formulations, 5th Edition</i> . American Pharmaceutical Association; 2012: 377.
13.	Fluticasone Propionate (Monograph). <i>United States Pharmacopeia XXXVIII / National Formulary 33</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2015: 3578.
14.	Pentoxifylline (Monograph). <i>United States Pharmacopeia XXXVIII / National Formulary 33</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2015: 4812.
15.	Fluticasone. Thomson Micromedex. <i>USP DI – Drug Information for the Health Care Professional, 26th Edition</i> . Taunton, MA: US Pharmacopeial Convention, Inc; 2006: 997.
16.	Pentoxifylline Systemic. Thomson Micromedex. <i>USP DI – Drug Information for the Health Care Professional, 26th Edition</i> . Taunton, MA: US Pharmacopeial Convention, Inc; 2006: 2419.
17.	USP <795>. <i>United States Pharmacopeia XXXVIII / National Formulary 33</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2015: 559.

DISCLAIMER: MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.